Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Kassambara, Alboukadel ^b   Hose, Dirk ^d   Moreaux, Jérôme ^a,b   Rème, Thierry ^a,b   Torrent, Jennifer ^a   Rossi, Jean François ^a   Goldschmidt, Hartmut ^d   Klein, Bernard ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; GENE IDENTIFICATION; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEMORY CELL; MESENCHYMAL STEM CELL; MONOCYTE; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; OVERALL SURVIVAL; PLASMA CELL; PLURIPOTENT STEM CELL; POLYMORPHONUCLEAR CELL; PROGNOSIS; T LYMPHOCYTE; TUMOR GENE;

ADULT STEM CELLS; CELL CYCLE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC MEMORY; MULTIPLE MYELOMA; PLURIPOTENT STEM CELLS; PROGNOSIS;

EID: 84864458523     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042161     Document Type: Article

References (51)

1. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, et al. ((2009)) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23:: 2210--2221.
2. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, et al. ((2010)) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116:: e56--65.
3. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, et al. ((2007)) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:: 2276--2284.
4. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, et al. ((2008)) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 26:: 4798--4805.
5. Hose D, Reme T, Hielscher T, Moreaux J, Meissner T, et al. ((2011)) Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica 96:: 87--95.
6. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, et al. ((2009)) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113:: 4331--4340.
7. Ghobrial IM, ((2012)) Myeloma as a model for the process of metastasis: implications for therapy. Blood 120:: 20--30.
8. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, et al. ((2004)) Characterization of clonogenic multiple myeloma cells. Blood 103:: 2332--2336.
9. Chiron D, Surget S, Maiga S, Bataille R, Moreau P, et al. ((2012)) The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol 156:: 679--683.
10. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. ((2007)) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:: 861--872.
11. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, et al. ((2011)) Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 9:: 433--446.
12. Schoenhals M, Kassambara A, Vos JD, Hose D, Moreaux J, et al. ((2009)) Embryonic stem cell markers expression in cancers. Biochemical and Biophysical Research Communications 383:: 157--162.
13. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, et al. ((2009)) An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114:: 5173--5181.
14. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, et al. ((2011)) Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol 187:: 3931--3941.
15. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, et al. ((2008)) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68:: 190--197.
16. Chiron D, Surget S, Maiga S, Bataille R, Moreau P, et al. ((2011)) The peripheral CD138(+) population but not the CD138(-) population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol.
17. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, et al. ((2011)) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117:: 4409--4419.
18. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, et al. ((2009)) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 113:: 4614--4626.
19. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, et al. ((2009)) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28:: 3866--3879.
20. Holien T, Vatsveen TK, Hella H, Rampa C, Brede G, et al. ((2011)) Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia.
21. Legg JA, Herbert JM, Clissold P, Bicknell R, ((2008)) Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis 11:: 13--21.
22. Brose K, Bland KS, Wang KH, Arnott D, Henzel W, et al. ((1999)) Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell 96:: 795--806.
23. Wang B, Xiao Y, Ding BB, Zhang N, Yuan X, et al. ((2003)) Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 4:: 19--29.
24. Schmid BC, Rezniczek GA, Fabjani G, Yoneda T, Leodolter S, et al. ((2007)) The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat 106:: 333--342.
25. Mahtouk K CF, Rème T, Jourdan M, Baudard M, Moreaux J, et al. ((2006)) Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 25:: 7180--7191.
26. Wessler I, Kirkpatrick CJ, Racke K, ((1999)) The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol 26:: 198--205.
27. Wessler I, Kilbinger H, Bittinger F, Kirkpatrick CJ, ((2001)) The biological role of non-neuronal acetylcholine in plants and humans. Jpn J Pharmacol 85:: 2--10.
28. Sperling LE, Steinert G, Boutter J, Landgraf D, Hescheler J, et al. ((2008)) Characterisation of cholinesterase expression during murine embryonic stem cell differentiation. Chem Biol Interact 175:: 156--160.
29. Paraoanu LE, Steinert G, Koehler A, Wessler I, Layer PG, ((2007)) Expression and possible functions of the cholinergic system in a murine embryonic stem cell line. Life Sci 80:: 2375--2379.
30. Szymanski P, Janik A, Zurek E, Mikiciuk-Olasik E, ((2011)) Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease. Pharmazie 66:: 399--403.
31. Bjerke GA, Hyman-Walsh C, Wotton D, ((2011)) Cooperative transcriptional activation by Klf4, Meis2, and Pbx1. Mol Cell Biol 31:: 3723--3733.
32. Barber KE, Harrison CJ, Broadfield ZJ, Stewart AR, Wright SL, et al. ((2007)) Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 46:: 478--486.
33. Chan KK, Zhang J, Chia NY, Chan YS, Sim HS, et al. ((2009)) KLF4 and PBX1 directly regulate NANOG expression in human embryonic stem cells. Stem Cells 27:: 2114--2125.
34. Jaruzelska J, Kotecki M, Kusz K, Spik A, Firpo M, et al. ((2003)) Conservation of a Pumilio-Nanos complex from Drosophila germ plasm to human germ cells. Dev Genes Evol 213:: 120--126.
35. Wang Z, Lin H, ((2004)) Nanos maintains germline stem cell self-renewal by preventing differentiation. Science 303:: 2016--2019.
36. Rickelt S, Winter-Simanowski S, Noffz E, Kuhn C, Franke WW, ((2009)) Upregulation of plakophilin-2 and its acquisition to adherens junctions identifies a novel molecular ensemble of cell-cell-attachment characteristic for transformed mesenchymal cells. Int J Cancer 125:: 2036--2048.
37. Groen RW, de Rooij MF, Kocemba KA, Reijmers RM, de Haan-Kramer A, et al. ((2011)) N-cadherin-mediated adhesion of multiple myeloma cells inhibits osteoblast differentiation. Haematologica.
38. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, et al. ((2005)) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106:: 1021--1030.
39. Moreaux J, Hose D, Kassambara A, Reme T, Moine P, et al. ((2011)) Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. Blood 117:: 1280--1290.
40. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, et al. ((2007)) Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21:: 1079--1088.
41. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, et al. ((1994)) Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:: 3654--3663.
42. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, et al. ((1998)) A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma. Blood 91:: 4727--4737.
43. Gu ZJ, Vos JD, Rebouissou C, Jourdan M, Zhang XG, et al. ((2000)) Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 14:: 188--197.
44. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, et al. ((2011)) A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96:: 574--582.
45. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, et al. ((2006)) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107:: 2633--2638.
46. Cremer FW, Bila J, Buck I, Kartal M, Hose D, et al. ((2005)) Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44:: 194--203.
47. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, et al. ((2008)) An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112:: 4235--4246.
48. Reme T, Hose D, De Vos J, Vassal A, Poulain PO, et al. ((2008)) A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics 9:: 16.
49. Tanguy Le Carrour SA, Sylvie Tondeur, Ludovic Lhermitte, Ned Lamb, Thierry Reme, et al. ((2010)) Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data. The Open Bioinformatics Journal 4 5-10.
50. Team RDC ((2008)) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
51. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. ((2004)) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:: R80.